每周的阿达利穆马布:一种有希望的方法来管理耐火性非传染性慢性儿科紫外炎
N Stolowy1, M Aubeleau1, K Mairot1
1Service d'ophtalmologie, hôpital de la Conception, AP-HM, Aix-Marseille université, chemin des Bourrely, 13015 Marseille, France; Aix-Marseille université, Marseille, France; Service d'ophtalmologie, hôpital Nord, AP-HM, Marseille, France.
Journal francais d'ophtalmologie
|November 11, 2025
概括
每周的阿达利穆马布 (Q1周) 有效地治疗了对两周一次剂量没有反应的儿童的慢性非传染性脑膜炎. 这种剂量升级导致活跃炎症和皮质类固醇使用显著减少,没有报告的副作用.
科学领域:
- 眼科医生 眼科 眼科
- 儿科 儿科 儿科
- 免疫学 免疫学 免疫学
背景情况:
- 儿童慢性非传染性脑膜炎带来了重大管理挑战.
- 对标准两周一次的阿达利穆马布 (Q2周) 反应不足,需要治疗升级.
- 阿达利穆马布是治疗儿科紫外炎的重要生物疗法.
研究的目的:
- 在患有慢性非传染性脑膜炎的儿科患者中,将阿达利穆马布剂量升级为每周 (Q1周) 的疗效和安全性进行评估.
- 评估剂量升级对炎症活性和皮质类固醇需求的影响.
- 确定本人群每周服用阿达利穆马布的安全性.
主要方法:
- 在第三级眼科部门进行了回顾性,单中心的研究.
- 包括患有慢性非传染性脑膜炎的儿科患者 (年龄小于16岁),需要从Q2周升至Q1周的阿达利穆马布剂量升级.
- 从2015年1月到2024年4月收集的数据.
主要成果:
- 80%的患者在升级到阿达利穆马布Q1周 (P=0.041) 后实现了活跃前部炎症的消失.
- 观察到局部和口服皮质类固醇使用的显著减少.
- 在接受口服类固醇的5/7名患者中,完全停止口服类固醇是可能的 (P=0.074).
- 没有报告与阿达利穆马布相关的不良反应.
结论:
- 升级至每周一次的阿达利穆马布 (Q1周) 是治疗儿童慢性非传染性脑膜炎的有希望的策略.
- 这种方法在解决炎症和减少对皮质类固醇的依赖方面表现出显著的有效性.
- 每周的阿达利穆马布在儿科患者中似乎是安全的,并且耐受性很好.
关键词:
这就是Adalimumab.阿达利穆马布每周使用一次.抗-TNF是一种抗 TNF 的.孩子 孩子 孩子 孩子婴儿婴儿的孩子们升级治疗方法.炎症 炎症是一种炎症.非传染性慢性脑膜炎是非传染性的.儿科 儿科 儿科儿科 儿科 儿科治疗升级治疗升级.一周一次的治疗.排卵管炎 排卵管炎 是一种乌维泰特 乌维泰特 的意思这是一种慢性非传染性疾病.周 周 周 周 周 周每周使用阿达利穆马布.更多相关视频
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
459
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
459
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
473
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
473
Open Angle Glaucoma: Treatment
940
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
940
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
470
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
470
Angle Closure Glaucoma: Treatment
1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
Nephrotic Syndrome II : Assessment and Medical Management
187
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
187


